The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans

키워드

참고문헌 (49)

1. "DHHS panelon antiretroviral guidelines for adults and adolescents.Guidelines for the use of antiretroviral agents in HIV-1 infectedadults and adolescents"[URL]
2. Aberg JA, "HIV MedicineAssociation of the Infectious Diseases Society ofAmerica. Primary care guidelines for the management ofpersons infected with human immunodeficiency virus:2009 update by the HIV medicine Association of the InfectiousDiseases Society of America", Clin Infect Dis, 49, pp.651~681 (2009)
3. "European Guidelines fortreatment of HIV-infected adults in Europe v7.0"[URL]
4. Hirsch MS, "Antiretroviraldrug resistance testing in adult HIV-1 infection: 2008recommendations of an International AIDS Society-USApanel", Clin Infect Dis, 47, pp.266~285 (2008)
5. Mallal S, "PREDICT-1 Study Team. HLAB*5701 screening for hypersensitivity to abacavir", N Engl JMed, 358, pp.568~579 (2008)
6. Kitahata MM, "NA-ACCORD Investigators. Effect of early versusdeferred antiretroviral therapy for HIV on survival", NEngl J Med, 360, pp.1815~1826 (2009)
7. Writing Committee for the CASCADE Collaboration, "Timingof HAART initiation and clinical outcomes in humanimmunodeficiency virus type 1 seroconverters", Arch InternMed, 171, pp.1560~1569 (2011)
8. Cohen MS, "HPTN 052 StudyTeam. Prevention of HIV-1 infection with early antiretroviraltherapy", N Engl J Med, 365, pp.493~505 (2011)
9. Hargrove JW, "ZVITAMBO Study Group.Mortality among HIV-positive postpartum women withhigh CD4 cell counts in Zimbabwe", AIDS, 24, pp.F11~F14 (2010)
10. Kalayjian RC, "Suppressionof HIV-1 replication by antiretroviral therapy improves renalfunction in persons with low CD4 cell counts andchronic kidney disease", AIDS, 22, pp.481~487 (2008)
11. Thio CL, "Multicenter AIDS Cohort Study.HIV-1, hepatitis B virus, and risk of liver-related mortalityin the Multicenter Cohort Study (MACS)", Lancet, 360, pp.1921~1926 (2002)
12. Matthews GV, "A randomized trial of combination hepatitis B therapy inHIV", HBV coinfected antiretroviral naive individuals inThailand, 2008, pp.48, 1062~1069
13. Peters MG, "ACTG ProtocolA5127 Team. Randomized controlled study of tenofovirand adefovir in chronic hepatitis B virus and HIV infection:ACTG A5127", Hepatology, 44, pp.1110~1116 (2006)
14. Egger M, "ARTCohort Collaboration. Prognosis of HIV-1-infected patientsstarting highly active antiretroviral therapy: a collaborative analys i s of prospect ive studies", Lancet, 360, pp.119~129 (2002)
15. Gianella S, "Effect of early antiretroviral therapy during primary HIV-1infection on cell-associated HIV-1 DNA and plasma HIV-1RNA", Antivir Ther, 16, pp.535~545 (2011)
16. Wyl Vv, "Early antiretroviral therapy during primaryHIV-1 infection results in a transient reduction ofthe viral setpoint upon treatment interruption", PLoS One, 6, pp.e27463~ (2011)
17. Sax PE, "AIDS Clinical TrialsGroup Study A5202 Team. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy", N Engl JMed, 361, pp.2230~2240 (2009)
18. Smith KY, "Randomized, double-blind,placebo-matched, multicenter trial of abacavir", lamivudineor tenofovir, ritonavir for initialHIV treatment, pp.AIDS, 2009[DOI]
19. Arribas JR, "Tenofovir disoproxil fumarate, emtricitabine,and efavirenz compared with zidovudine", lamivudineand efavirenz in treatment-naive patients: 144-weekanalysis, 2008, pp.47, 74~78
20. Berenguer J, "Didanosine, lamivudine, and efavirenz versuszidovudine, lamivudine, and efavirenz for the initial treatmentof HIV type 1 infection: final analysis (48 weeks) of aprospective, randomized, noninferiority clinical trial, GESIDA3903", Clin Infect Dis, 47, pp.1083~1092 (2008)
21. Orkin C, "Final 192-week efficacy and safety of once-dailydarunavir", ritonavir compared with lopinavir, HIV Med, pp.2013, 14[DOI]
22. Molina JM, "CASTLEStudy Team. Once-daily atazanavir", ritonavir comparedwith twice-daily lopinavir, J AcquirImmune Defic Syndr, pp.2010, 53[DOI]
23. Riddler SA, "AIDS Clinical Trials Group Study A5142 Team.Class-sparing regimens for initial treatment of HIV-1 infection", N Engl J Med, 358, pp.2095~2106 (2008)
24. Malan DR, "089 Study Group. Efficacy and safety of atazanavir,with or without ritonavir, as part of once-daily highlyactive antiretroviral therapy regimens in antiretroviral-naivepatients", J Acquir Immune Defic Syndr, 47, pp.161~167 (2008)
25. Molina JM, "ECHO and THRIVE Study Groups. Week 96analysis of rilpivirine or efavirenz in HIV-1-infected patientswith baseline viral load ≤ 100 000 copies", mL in thepooled ECHO and THRIVE phase 3, randomized, doubleblindtrials, 2014, pp.15, 57~62
26. Molina JM, "ECHO Study Group; THRIVE Study Group.Rilpivirine vs. efavirenz in HIV-1 patients with baseline viralload 100,000 copies", ml or less: week 48 phase III analysis, 2013, pp.27, 889~897
27. Rockstroh JK, "STARTMRK Investigators. Durable efficacy and safety of raltegravirversus efavirenz when combined with tenofovir", emtricitabinein treatment-naive HIV-1-infected patients: final5-year results from STARTMRK, 2013, pp.63, 77~85
28. Ledergerber B, "PLATO Collaboration. Predictors oftrend in CD4-positive T-cell count and mortality amongHIV-1-infected individuals with virological failure to allthree antiretroviral-drug classes", Lancet, 364, pp.51~62 (2004)
29. Matthews GV, "Combination HBV therapy is linked togreater HBV DNA suppression in a cohort of lamivudineexperiencedHIV", HBV coinfected individuals, 2009, pp.23, 1707~1715
30. de Vries-Sluijs TE, "Long-term therapy with tenofovir is effective for patientsco-infected with human immunodeficiency virus andhepatitis B virus", Gastroenterology, 139, pp.1934~1941 (2010)
31. Pessoa MG, "Efficacy and safety of entecavir for chronicHBV in HIV", HBV coinfected patients receiving lamivudineas part of antiretroviral therapy, 2008, pp.22, 1779~1787
32. Benhamou Y, "Safety and efficacy of adefovir dipivoxil in patientsco-infected with HIV-1 and lamivudine-resistanthepatitis B virus: an open-label pilot study", Lancet, 358, pp.718~723 (2001)
33. Ingiliz P, "Efficacy and safetyof adefovir dipivoxil plus pegylated interferon-alpha2a forthe treatment of lamivudine-resistant hepatitis B virus infectionin HIV-infected patients", Antivir Ther, 13, pp.895~900 (2008)
34. McMahon MA, "The HBV drug entecavir -effects on HIV-1 replication and resistance", N Engl J Med, 356, pp.2614~2621 (2007)
35. Dore GJ, "SMART INSIGHT study group. Frequent hepatitisB virus rebound among HIV-hepatitis B virus-coinfectedpatients following antiretroviral therapy interruption", AIDS, 24, pp.857~865 (2010)
36. Ge D, "Genetic variation inIL28B predicts hepatitis C treatment-induced viral clearance", Nature, 461, pp.399~401 (2009)
37. Thomas DL, "Geneticvariation in IL28B and spontaneous clearance of hepatitisC virus", Nature, 461, pp.798~801 (2009)
38. Rauch A, "Genetic variation in IL28B is associatedwith chronic hepatitis C and treatment failure: agenome-wide association study", Gastroenterology, 138, pp.1338~1345 (2010)
39. Ghany MG, "Progressionof fibrosis in chronic hepatitis C", Gastroenterology, 124, pp.97~104 (2003)
40. Macias J, "Fast fibrosisprogression between repeated liver biopsies in patientscoinfected with human immunodeficiency virus", hepatitisC virus, 2009, pp.50, 1056~1063
41. Verma S, "Hepatic steatosis in patientswith HIV-Hepatitis C Virus coinfection: is it associatedwith antiretroviral therapy and more advanced hepatic fibrosis", BMC Res Notes, 1, pp.46~ (2008)
42. Ragni MV, "Highly activeantiretroviral therapy improves ESLD-free survival in HIVHCVco-infection", Haemophilia, 15, pp.552~558 (2009)
43. Alvarez D, "Zidovudine use but not weight-based ribavirindosing impacts anaemia during HCV treatment in HIV-infected persons", J Viral Hepat, 13, pp.683~689 (2006)
44. Vispo E, "Low response to pegylatedinterferon plus ribavirin in HIV-infected patientswith chronic hepatitis C treated with abacavir", Antivir Ther, 13, pp.429~437 (2008)
45. Laufer N, "Abacavir does notinfluence the rate of virological response in HIV-HCVcoinfectedpatients treated with pegylated interferon andweight-adjusted ribavirin", Antivir Ther, 13, pp.953~957 (2008)
46. Mira JA, "Efficacy of pegylatedinterferon plus ribavirin treatment in HIV", hepatitisC virus co-infected patients receiving abacavir plus lamivudineor tenofovir plus either lamivudine oremtricitabine as nucleoside analogue backbone, 2008, pp.62, 1365~1373
47. Aranzabal L, "Influence of liverfibrosis on highly active antiretroviral therapy-associatedhepatotoxicity in patients with HIV and hepatitis C viruscoinfection", Clin Infect Dis, 40, pp.588~593 (2005)
48. Nunez M, "Hepatotoxicity of antiretrovirals: incidence,mechanisms and management", J Hepatol, 44(1), pp.S132~S139 (2006)
49. McGovern BH, "Hepatic steatosis is associated with fibrosis, nucleosideanalogue use, and hepatitis C virus genotype 3 infectionin HIV-seropositive patients", Clin Infect Dis, 43, pp.365~372 (2006)

관련 논문AI추천